| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
APEN Stock Overview
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices.
Apollo Endosurgery Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.92 |
| 52 Week High | US$10.39 |
| 52 Week Low | US$3.58 |
| Beta | 2.27 |
| 1 Month Change | -29.88% |
| 3 Month Change | -28.07% |
| 1 Year Change | -44.24% |
| 3 Year Change | 12.00% |
| 5 Year Change | -40.06% |
| Change since IPO | -67.76% |
Recent News & Updates
Is Apollo Endosurgery (NASDAQ:APEN) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Shareholder Returns
| APEN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -8.2% | 0.5% | -2.7% |
| 1Y | -44.2% | -16.2% | -12.9% |
Return vs Industry: APEN underperformed the US Medical Equipment industry which returned -16.2% over the past year.
Return vs Market: APEN underperformed the US Market which returned -12.9% over the past year.
Price Volatility
| APEN volatility | |
|---|---|
| APEN Average Weekly Movement | 10.0% |
| Medical Equipment Industry Average Movement | 10.6% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: APEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: APEN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 202 | Chas McKhann | https://www.apolloendo.com |
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands.
Apollo Endosurgery Fundamentals Summary
| APEN fundamental statistics | |
|---|---|
| Market Cap | US$157.78m |
| Earnings (TTM) | -US$28.49m |
| Revenue (TTM) | US$65.79m |
2.4x
P/S Ratio-5.5x
P/E RatioIs APEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APEN income statement (TTM) | |
|---|---|
| Revenue | US$65.79m |
| Cost of Revenue | US$28.97m |
| Gross Profit | US$36.83m |
| Other Expenses | US$65.32m |
| Earnings | -US$28.49m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 55.97% |
| Net Profit Margin | -43.31% |
| Debt/Equity Ratio | 96.6% |
How did APEN perform over the long term?
See historical performance and comparisonValuation
Is Apollo Endosurgery undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
2.87x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate APEN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate APEN's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: APEN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: APEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APEN is overvalued based on its PB Ratio (2.9x) compared to the US Medical Equipment industry average (2.4x).
Future Growth
How is Apollo Endosurgery forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
6.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APEN's revenue (25% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: APEN's revenue (25% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if APEN's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Apollo Endosurgery performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
10.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APEN is currently unprofitable.
Growing Profit Margin: APEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APEN is unprofitable, but has reduced losses over the past 5 years at a rate of 10.9% per year.
Accelerating Growth: Unable to compare APEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.5%).
Return on Equity
High ROE: APEN has a negative Return on Equity (-51.78%), as it is currently unprofitable.
Financial Health
How is Apollo Endosurgery's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: APEN's short term assets ($108.5M) exceed its short term liabilities ($14.0M).
Long Term Liabilities: APEN's short term assets ($108.5M) exceed its long term liabilities ($56.0M).
Debt to Equity History and Analysis
Debt Level: APEN has more cash than its total debt.
Reducing Debt: APEN's debt to equity ratio has increased from 95.6% to 96.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APEN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: APEN has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 4.4% each year.
Dividend
What is Apollo Endosurgery current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as APEN has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.4yrs
Average management tenure
CEO
Chas McKhann (52 yo)
1.17yrs
Tenure
US$8,664,627
Compensation
Mr. Charles S. McKhann, also known as Chas, serves as President, Chief Executive Officer and Director at Apollo Endosurgery, Inc since March 01, 2021. He served as Chief Commercial Officer at Torax Medical...
CEO Compensation Analysis
Compensation vs Market: Chas's total compensation ($USD8.66M) is above average for companies of similar size in the US market ($USD1.67M).
Compensation vs Earnings: Insufficient data to compare Chas's compensation with company performance.
Leadership Team
Experienced Management: APEN's management team is considered experienced (3.4 years average tenure).
Board Members
Experienced Board: APEN's board of directors are considered experienced (6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: APEN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.9%.
Top Shareholders
Company Information
Apollo Endosurgery, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Apollo Endosurgery, Inc.
- Ticker: APEN
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$157.782m
- Shares outstanding: 40.25m
- Website: https://www.apolloendo.com
Number of Employees
Location
- Apollo Endosurgery, Inc.
- Building 1
- Suite 300
- Austin
- Texas
- 78746
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/22 00:00 |
| End of Day Share Price | 2022/05/20 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.